CN114502183A - 用于阻抑病原生物体的组合物和方法 - Google Patents

用于阻抑病原生物体的组合物和方法 Download PDF

Info

Publication number
CN114502183A
CN114502183A CN202080070802.3A CN202080070802A CN114502183A CN 114502183 A CN114502183 A CN 114502183A CN 202080070802 A CN202080070802 A CN 202080070802A CN 114502183 A CN114502183 A CN 114502183A
Authority
CN
China
Prior art keywords
clostridium
bacteroides
composition
faecalis
resistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080070802.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·卡巴莱罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vedanta Biosciences Inc
Original Assignee
Vedanta Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vedanta Biosciences Inc filed Critical Vedanta Biosciences Inc
Publication of CN114502183A publication Critical patent/CN114502183A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080070802.3A 2019-08-09 2020-08-07 用于阻抑病原生物体的组合物和方法 Pending CN114502183A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962884917P 2019-08-09 2019-08-09
US62/884,917 2019-08-09
US201962901206P 2019-09-16 2019-09-16
US62/901,206 2019-09-16
US201962947517P 2019-12-12 2019-12-12
US62/947,517 2019-12-12
US202063031299P 2020-05-28 2020-05-28
US63/031,299 2020-05-28
PCT/US2020/045442 WO2021030198A1 (en) 2019-08-09 2020-08-07 Compositions and methods for suppressing pathogenic organisms

Publications (1)

Publication Number Publication Date
CN114502183A true CN114502183A (zh) 2022-05-13

Family

ID=74571198

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080070802.3A Pending CN114502183A (zh) 2019-08-09 2020-08-07 用于阻抑病原生物体的组合物和方法

Country Status (5)

Country Link
US (1) US20220409674A1 (https=)
EP (1) EP4010013A4 (https=)
JP (1) JP7846613B2 (https=)
CN (1) CN114502183A (https=)
WO (1) WO2021030198A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3706767A4 (en) * 2017-11-09 2021-12-15 Vedanta Biosciences, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF AN ALLERGY
EP3723776A4 (en) 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
GB202217266D0 (en) * 2022-11-18 2023-01-04 Imperial College Innovations Ltd Anti-biotic-resistant bacteria
EP4687930A2 (en) * 2023-01-30 2026-02-11 Seres Therapeutics, Inc. Use of designed bacterial compositions for infection treatment
EP4687931A1 (en) * 2023-04-04 2026-02-11 Vedanta Biosciences, Inc. Compositions and methods for treating or preventing clostridium difficile infection, neutropenia, cardiovascular disease, asthma, and/or cancer
WO2025166242A1 (en) * 2024-02-01 2025-08-07 Vedanta Biosciences, Inc. Compositions and methods for decreasing dysbiosis and/or preventing inflammatory bowel disease
EP4663196A1 (en) 2024-06-13 2025-12-17 Helmholtz-Zentrum für Infektionsforschung GmbH Decolonization of pathogenic enterobacteria, such as e. coli and/or klebsiella pneumoniae, from the gut using strains of e. coli

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198252A (zh) * 2005-04-18 2008-06-11 加利福尼亚大学董事会 用于细菌感染的抗微生物疗法
WO2014182635A1 (en) * 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
CN109640688A (zh) * 2016-09-02 2019-04-16 雀巢产品技术援助有限公司 用于调节犬科动物的胃肠微生物区系的组合物和方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) * 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
US10973861B2 (en) * 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US9999641B2 (en) * 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
US20180000872A1 (en) * 2016-07-01 2018-01-04 Regents Of The University Of Minnesota Compositions and methods for c. difficile treatment
WO2018023003A1 (en) * 2016-07-29 2018-02-01 Isothrive Llc Optimized individualized prebiotic compositions
WO2018136884A1 (en) * 2017-01-23 2018-07-26 The Regents Of The University Of California Compositions and methods for treating obesity and inducing weight loss
AU2018302641B2 (en) * 2017-07-18 2024-12-19 Keio University Anti-bacterial composition against Th1 cell-inducing bacteria
EP3723776A4 (en) * 2017-12-11 2022-07-27 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
CN117202919A (zh) * 2021-02-18 2023-12-08 韦丹塔生物科学股份有限公司 用于抑制病原生物体的组合物和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198252A (zh) * 2005-04-18 2008-06-11 加利福尼亚大学董事会 用于细菌感染的抗微生物疗法
WO2014182635A1 (en) * 2013-05-08 2014-11-13 Baldwin Megan E Biomarkers for age-related macular degeneration (amd)
CN109640688A (zh) * 2016-09-02 2019-04-16 雀巢产品技术援助有限公司 用于调节犬科动物的胃肠微生物区系的组合物和方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王英春;丛桂敏;: "血清PCT检验对妇科感染性疾病治疗过程的价值", 中国卫生工程学, no. 02 *

Also Published As

Publication number Publication date
JP7846613B2 (ja) 2026-04-15
EP4010013A1 (en) 2022-06-15
US20220409674A1 (en) 2022-12-29
EP4010013A4 (en) 2023-12-06
WO2021030198A1 (en) 2021-02-18
JP2022544380A (ja) 2022-10-18

Similar Documents

Publication Publication Date Title
US20250009811A1 (en) Compositions and methods for suppressing pathogenic organisms
US12390498B2 (en) Treatment of clostridium difficile infection
CN114502183A (zh) 用于阻抑病原生物体的组合物和方法
US11701396B2 (en) Treatment of Clostridium difficile infection
KR20200136365A (ko) 공동선택 미생물총을 포함하는 조성물 및 그 이용 방법
CN117202919A (zh) 用于抑制病原生物体的组合物和方法
HK1044964A1 (zh) 用於治療炎性疾病的雙岐桿菌
WO2024227021A2 (en) Compositions and methods for treating clostridioides difficile infection
HK40114606A (en) Compositions and methods for suppressing pathogenic organisms
HK40104391A (en) Treatment of clostridium difficile infection
HK40007703B (en) Treatment of clostridium difficile infection
HK40007703A (en) Treatment of clostridium difficile infection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination